CC
CYTK icon

Centiva Capital’s Cytokinetics CYTK Stock Holding History

Centiva Capital’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$426K Sell
5,000
-50,000
-91% -$3.59M ﹤0.01% 997
2026
Q1 		$3.63M Buy
55,000
+41,300
+301% +$2.62M 0.03% 322
2025
Q4 		$870K Hold
13,700
– – 0.01% 599
2025
Q3 		$753K Buy
+13,700
New +$564K 0.01% 551
2024
Q2 		– Sell
-10,000
Closed -$701K – 2148
2024
Q1 		$701K Buy
10,000
+9,500
+1,900% +$735K 0.02% 839
2023
Q4 		$41.7K Buy
+500
New +$18.1K ﹤0.01% 1655

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Centiva Capital's CYTK Position: Q2 2026 in Review

Centiva Capital increased its Cytokinetics (CYTK) stake by 221% in Q2 2026, buying an estimated $477K and bringing the position to 9,643 shares worth $821K. The position accounts for 0.01% of the portfolio, ranked #709.

Centiva Capital first reported a position in CYTK in Q1 2023 and has held it in 9 quarters since. The position peaked at $1.16M in Q1 2024. 484 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • Centiva Capital held 9,643 shares of Cytokinetics worth $821K as of Q2 2026.
  • Centiva Capital bought 6,643 Cytokinetics shares in Q2 2026, an estimated $477K.
  • Cytokinetics made up 0.01% of Centiva Capital's portfolio in Q2 2026, its #709 holding.
  • Centiva Capital first reported a position in Cytokinetics in Q1 2023 and has held it in 9 quarters since.
  • Centiva Capital's Cytokinetics position peaked at $1.16M in Q1 2024.
  • 484 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Centiva Capital's 13F filing for Q2 2026, filed 13 Aug 2026.